Brief: Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD
10/06/2025 14:24
June 10 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS® ANNOUNCES SMC RECOMMENDATION OF LYTENAVA™ (BEVACIZUMAB GAMMA) FOR THE TREATMENT OF WET AMD Source text: ID:nGNXbkFHBv Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce